Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
Zhigang Liu, Kaixing Le, Xin Zhou, CLARITY study investigators, James L. Alexander, Simeng Lin, Claire Bewshea, Neil Chanchlani, Rachel Nice, Timothy J. McDonald, Christopher A. Lamb, Shaji Sebastian, Klaartje Kok, Charlie W. Lees, Ailsa L. Hart, Richard C. Pollok, Rosemary J. Boyton, Daniel M. Altmann, Katrina M. Pollock, James R. GoodhandNicholas A. Kennedy, Tariq Ahmad
Research output: Contribution to journal › Article › Academic › peer-review
25Citations
(Scopus)
2Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study'. Together they form a unique fingerprint.